Akari Therapeutics grants executive stock options

The chief business officer’s option award is subject to forfeiture if shareholders do not approve a proposed increase to the equity plan’s share reserve.

Rhea-AI Filing Summary

Akari Therapeutics Plc (AKTX) Chief Business Officer Vat-Ho Vatnak received an option grant to purchase 87,000 ADSs. The award transaction is dated October 12, 2026; the stated Grant Date is October 5, 2026. The options have an exercise price of $8.94 per ADS and are subject to forfeiture and cancellation if shareholders do not approve a proposed increase in the equity plan’s share reserve. They vest 25% on the Grant Date’s 12-month anniversary, then in equal monthly installments over the next 36 months, subject to continued service, with full vesting on the 4-year anniversary.

Insider Trade Summary

Grant/Award: 87,000 shares

Grant/Award 1 txn

Insider Vat-Ho Vatnak

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	87,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 87,000 contracts (Direct)

Footnotes (1)

1. F1. On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.

Key Figures

Underlying ADSs: 87,000 ADSs Exercise price: $8.94 per ADS Initial vesting: 25% +2 more

5 metrics

Underlying ADSs 87,000 ADSs ADSs covered by the option grant

Exercise price $8.94 per ADS Price to purchase each ADS under the option

Initial vesting 25% On the 12-month anniversary of the October 5, 2026 Grant Date

Remaining vesting period 36 months Equal monthly installments after initial vesting

Option expiration October 5, 2036 Expiration date of the option

Key Terms

American Depositary Shares, exercise price, equity incentive plan, vesting

4 terms

American Depositary Shares financial

"American Depositary Shares representing Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"option exercise price of $8.94 per ADS"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"proposed amendment to the Issuer's equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"will vest with respect to 25% on the 12-month anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did AKTX Chief Business Officer Vat-Ho Vatnak receive?

Vat-Ho Vatnak received an option grant to purchase 87,000 ADSs at an exercise price of $8.94 per ADS. The award transaction is dated October 12, 2026, while the stated Grant Date is October 5, 2026.

When do AKTX’s options granted to Vat-Ho Vatnak vest?

The options vest 25% on the 12-month anniversary of October 5, 2026, with the remainder vesting in equal monthly installments over the next 36 months. Vesting is subject to the grantee’s continued service, and the options are fully vested on the 4-year anniversary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 05:22 PM EDT Accepted by SEC EDGAR 10/14/2026 - 05:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vat-Ho Vatnak

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA FLORIDA 33602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.94	10/12/2026		A		87,000		(1)	10/05/2036	American Depositary Shares representing Ordinary Shares	87,000	$0	87,000	D

Explanation of Responses:

1. On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)